Ukraine proposes $100 bln US weapons deal for security guarantees - FT
NEW YORK - SBC Medical (TASE:BLWV) Group Holdings Incorporated (NASDAQ:SBC) saw its stock tumble 11.2% after reporting fourth-quarter earnings that fell short of analyst expectations. The global cosmetic treatment center operator posted weaker-than-anticipated revenue and profits amid challenging market conditions.
SBC Medical reported Q4 earnings per share of $0.06, missing the analyst estimate of $0.19 by $0.13. Revenue for the quarter came in at $44 million, well below the consensus estimate of $56 million and representing a 29% YoY decrease.
The company’s Q4 net income attributable to SBC Medical Group was $7 million, down 54% YoY. Total (EPA:TTEF) revenues declined 29% YoY to $44 million, which the company attributed to a challenging competitive environment in Japan’s aesthetic medical industry.
"The year of 2024 was a momentous year for us, showcasing our solid performance and sustained growth, culminating in our successful Nasdaq listing," said Yoshiyuki Aikawa, Chairman and CEO of SBC Medical. "We delivered strong 2024 results with top line growing by 6% while bottom line surged 18% year over year."
Despite the Q4 miss, SBC Medical reported full-year 2024 revenues of $205 million, up 6% YoY. The company served 6.03 million customers in 2024, a 15% YoY increase, across its network of 251 partner clinics.
Looking ahead, SBC Medical expects continued expansion of the aesthetic dermatology market in fiscal year 2025, but also anticipates intensifying competition. The company plans to implement strategic price revisions and a new franchise fee structure starting in April 2025 to support long-term growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.